Kite Pharma to Present at June 2016 Investor Conferences
Get Alerts KITE Hot Sheet
Join SI Premium – FREE
SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq: KITE) today announced that management will present at two investor conferences in June:
Jefferies 2016 Healthcare Conference
- Date: Tuesday, June 7, 2016
- Time: 11:00 AM EDT
- Location: New York, NY
Goldman Sachs 37th Annual Healthcare Conference
- Date: Tuesday, June 7, 2016
- Time: 11:20 AM PDT
- Location: Palos Verdes, CA
A live audio webcast of both presentations will be available on the Investors section of Kite's website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
About Kite Pharma
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACTâ„¢) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160527005092/en/
Kite Pharma, Inc.
Greg Mann
VP, Investor Relations
[email protected]
or
For
Media:
inVentiv Health
David Polk, 310-309-1029
[email protected]
or
Anne
Cummings, 212-845-5632
[email protected]
or
Burns
McClellan
Justin Jackson, 212-213-0006
[email protected]
Source: Kite Pharma, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
- PB Financial Group Responds to Rising Demand for Hard Money Loans as California Borrowers Face Tighter Bank Lending
- Davis Commodities Limited Announces Receipt of Nasdaq Final Action Letter
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Goldman Sachs, Jefferies & Co, TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share